Skandinaviska Enskilda Banken AB publ Has $8.98 Million Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Key Points

• Skandinaviska Enskilda Banken AB increased its stake in Natera, Inc. by 63.7% in the first quarter, owning a total of 63,499 shares valued at approximately $8.98 million.
• Natera's quarterly earnings report exceeded expectations, with revenue of $501.83 million and a loss of ($0.50) per share, surpassing the consensus estimate of ($0.59).
• Analysts have mixed ratings for Natera, with twelve maintaining a "buy" rating and a consensus target price of $184.63, while UBS recently raised its price target to $218.00.

Skandinaviska Enskilda Banken AB publ raised its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 63.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,499 shares of the medical research company's stock after purchasing an additional 24,700 shares during the period. Skandinaviska Enskilda Banken AB publ's holdings in Natera were worth $8,979,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. LRI Investments LLC purchased a new position in Natera during the 4th quarter valued at about $29,000. Rakuten Securities Inc. grew its stake in shares of Natera by 117.8% in the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after buying an additional 119 shares during the last quarter. ORG Partners LLC purchased a new stake in shares of Natera in the 1st quarter worth approximately $32,000. ANTIPODES PARTNERS Ltd purchased a new stake in Natera during the 1st quarter valued at $40,000. Finally, Covestor Ltd boosted its stake in Natera by 42.7% during the 4th quarter. Covestor Ltd now owns 531 shares of the medical research company's stock valued at $84,000 after purchasing an additional 159 shares during the last quarter. Institutional investors own 99.90% of the company's stock.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of recent research reports. Wall Street Zen cut Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Barclays boosted their price target on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a report on Friday, May 9th. Piper Sandler boosted their price objective on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Thursday, May 15th. Evercore ISI raised Natera to a "strong-buy" rating and set a $170.00 target price on the stock in a research report on Monday. Finally, UBS Group increased their price target on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $183.76.

Natera Trading Up 2.1%

NASDAQ NTRA traded up $2.83 during trading hours on Wednesday, reaching $138.67. 227,756 shares of the company traded hands, compared to its average volume of 1,488,607. The company has a 50 day moving average of $158.12 and a two-hundred day moving average of $156.45. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00. The stock has a market capitalization of $18.93 billion, a PE ratio of -94.32 and a beta of 1.73.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The company had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. During the same quarter in the previous year, the company posted ($0.56) EPS. The business's revenue was up 36.5% compared to the same quarter last year. On average, equities research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Transactions at Natera

In other news, CEO Steven Leonard Chapman sold 1,622 shares of Natera stock in a transaction that occurred on Monday, July 21st. The shares were sold at an average price of $139.29, for a total value of $225,928.38. Following the transaction, the chief executive officer owned 175,492 shares of the company's stock, valued at $24,444,280.68. This trade represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John Fesko sold 339 shares of Natera stock in a transaction that occurred on Monday, July 21st. The shares were sold at an average price of $139.29, for a total transaction of $47,219.31. Following the completion of the transaction, the insider directly owned 153,460 shares in the company, valued at approximately $21,375,443.40. This represents a 0.22% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 47,844 shares of company stock valued at $7,488,466. Insiders own 7.60% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.